Screener
Amneal Pharmaceuticals, Inc. AMRX Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
FAQ
- What is Amneal Pharmaceuticals, Inc.'s retained earnings?
- Amneal Pharmaceuticals, Inc. (AMRX) reported retained earnings of -$415.09M in Q2 2026.
- How has Amneal Pharmaceuticals, Inc.'s retained earnings changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s retained earnings increased by 27.5% year-over-year, from -$572.45M to -$415.09M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s retained earnings?
- Over 5 years (2020 to 2025), Amneal Pharmaceuticals, Inc.'s retained earnings has grown at a 13.3% compound annual growth rate (CAGR), from -$286.82M to -$535.01M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Amneal Pharmaceuticals, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude